Is S-309309 Approved? Current Status and MGAT2 Timeline (2026)
No. S-309309 is still a Phase 2 asset. It is a mid-stage non-incretin program, not a near-term approval story.
Current stage
Phase 2
Approval read
Not approved.
Likely window
2028 or later if development continues successfully.
Next step
Show enough mid-stage differentiation to justify a much bigger development commitment.
Direct answer
No. S-309309 is still a Phase 2 asset. It is a mid-stage non-incretin program, not a near-term approval story.
Status facts for search and AI answers
What this S-309309 status page answers
Compound
S-309309
S-309309 is tracked as a MGAT2 inhibitor program from Shionogi.
Approval read
Not approved.
No. S-309309 is still a Phase 2 asset. It is a mid-stage non-incretin program, not a near-term approval story.
Likely window
2028 or later if development continues successfully.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Show enough mid-stage differentiation to justify a much bigger development commitment.
This is the milestone most likely to change the page's answer.
Decision path
What does S-309309's status mean for access?
S-309309's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- S-309309
- Stage
- Phase 2
- Approval read
- Not approved.
- Window
- 2028 or later if development continues successfully.
Step 1
Classify availability
Phase 2 MGAT2-inhibitor program that still has to prove it deserves broad attention.
Read compound pageStep 2
Watch required milestone
Show enough mid-stage differentiation to justify a much bigger development commitment.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2 MGAT2-inhibitor program that still has to prove it deserves broad attention.
S-309309 matters because the non-incretin field still needs more than one or two recognizable mechanisms if it wants to become a real category.
What needs to happen next
Show enough mid-stage differentiation to justify a much bigger development commitment.
What FormBlends is watching
- Whether MGAT2 inhibition looks clinically relevant enough to matter
- How visible the sponsor wants to make the asset
- Whether the program keeps moving or drifts into the background
What could delay the timeline
- Low mindshare
- Mid-stage data that never forces a bigger conversation
- Being overshadowed by more headline-friendly mechanisms